Vytorin is indicated as adjunct to diet in primary hyperlipidemia (heterozygous familial and non-familial) or mixed hyperlipidemia: to reduce elevated total-C, LDL-C, apo B, TG and non-HDL-C, and to increase HDL-C; and as adjunct to or when other lipid-lowering treatments for homozygous familial hypercholesterolemia (HoFH) are not available: to reduce elevated total-C and LDL-C.
Vytorin contains ezetimibe, a cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor. Ezetimibe lowers blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. Simvastatin, a prodrug, is hydrolyzed to its active form, simvastatin acid. It inhibits the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.
Ezemtimibe and Simvastatin Tablets are available as 10/10mg, 10/20mg, 10/40mg, and 10/80mg strengths for both brands.